Association between GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown EGFR mutation status

Chinese Journal of Lung Cancer

Volumn 17, Issue 4, 2014, Pages 321-326

  Hong, Wei ^a   Lin, Bao Chai ^b   Zhang, Bei Bei ^c   Mao, Wei Min ^a   Zhang, Yi Ping ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

GNAS1 gene; Lung neoplasms; Polymorphism; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

ADVANCED CANCER; ARTICLE; DNA POLYMORPHISM; DRUG EFFICACY; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; GNAS1 GENE; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PERIPHERAL LYMPHOCYTE; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; SMOKING;

EID: 84940343878     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2014.04.06     Document Type: Article

References (20)

1. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362(25): 2380-2388.
2. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol, 2006, 24(31): 5034-5042.
3. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005, 353(2): 123-132.
4. Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study Lancet Oncol, 2012, 13(3): 300-308.
5. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 2008, 372(9652): 1809-1818.
6. Chang CY, Shen CC, Su HL, et al. Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation. J Neurooncol, 2011, 105(3): 507-522.
7. Frey UH, Alakus H, Wohlschlaeger J, et al. GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res, 2005, 11(14): 5071-5077.
8. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature, 1997, 390(6655): 88-91.
9. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009, 45(2): 228-247.
10. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol, 2011, 12(8): 735-742.
11. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11(2): 121-128.
12. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362(25): 2380-2388.
13. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012, 13(3): 239-246.
14. Engelman JA, Janne PA. Factors predicting response to EGFR tyrosine kinase inhibitors. Semin Respir Crit Care Med, 2005, 26(3): 314-322.
15. Costa DB, Halmos B, Kumar A, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med, 2007, 4(10): 1669-1679.
16. Ng KP, Hillmer AM, Chuah CT, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med, 2012, 18(4): 521-528.
17. Zou M, Xia S, Zhuang L, et al. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation. Int J Oncol, 2013, 42(6): 2094-2102.
18. Zannetti A, Iommelli F, Fonti R, et al. Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3. Clin Cancer Res, 2008, 14(16): 5209-5219.
19. Lehnerdt GF, Franz P, Zaqoul A, et al. Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene. Clin Cancer Res, 2008, 14(6): 1753-1758.
20. Xie FJ, Zhao P, Kou JY, et al. The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum. Cancer Chemother Pharmacol, 2012, 69(6): 1443-1448.